Full text is available at the source.
Abstract
Essence
Ketamine-linked circuit mechanisms pointed to mPFC somatostatin-interneuron GPCR targets with antidepressant-like effects in preclinical models.
Evidence
Mechanistic preclinical study combined ketamine experiments, chronic-stress circuit analysis, RNA sequencing of mPFC SstIN-enriched GPCRs, and target validation for antidepressant-like responses.
Caveat
The therapeutic claims come from molecular, circuit, and behavioral preclinical experiments, so human efficacy and side-effect reduction remain untested.
Simplified
Psychedelic Science